Introduction {#section1-1533034617740475}
============

Accumulated evidence demonstrated that DNA methylation, a key epigenetic modificator, plays essential roles in tumorigenesis.^[@bibr1-1533034617740475],[@bibr2-1533034617740475]^ Indeed, aberrant DNA methylation profiles have been found in almost all types of cancers.^[@bibr3-1533034617740475]^ Generally, DNA methylation patterns in mammals are established by the *de novo* methyltransferase (DNMT) 3 family (DNMT3A and DNMT3B) and maintained by the maintenance methyltransferase (DNMT1).^[@bibr1-1533034617740475],[@bibr2-1533034617740475]^ Therefore, the alteration in global DNA methylation patterns may be largely attributed to the dysregulation of *de novo* DNMTs during tumor progression.^[@bibr4-1533034617740475],[@bibr5-1533034617740475]^ Interestingly, previous studies have suggested that DNMT3B promotes tumorigenesis, and abnormal expression of DNMT3B contributes to the aberrant DNA methylation in carcinogenesis.^[@bibr6-1533034617740475]^

Lung and gastric cancers have been the leading cancer diagnosed and are the cause of cancer death for many years in Hubei province of China, and the incidences still increase rapidly.^[@bibr7-1533034617740475][@bibr8-1533034617740475]--[@bibr9-1533034617740475]^ More seriously, most patients with lung and gastric cancers are detected in advanced stage, during which period the tumors are unresectable anymore.^[@bibr10-1533034617740475],[@bibr11-1533034617740475]^ Thus, it is no doubt that discovery of genetic biomarkers and their application accompanied with traditional diagnosis may be more efficiency for risk prediction and early diagnosis of lung and gastric cancer.

On the other side, it had been proved that certain functional single-nucleotide polymorphisms (SNPs) in the 5'-untranslated regions of genes could influence promoter activity and then expression of genes.^[@bibr12-1533034617740475]^ Therefore, identification of functional SNPs in *DNMT3B* gene would lead to a better understanding of how DNMT3B contributes to individuals' susceptibility to cancer. Recently, the -149C\>T (rs2424913) and -579G\>T (rs1569686) polymorphisms in *DNMT3B* gene promoter, which may be able to alter promoter activity, have been widely studied for their association with cancer susceptibility.^[@bibr13-1533034617740475][@bibr14-1533034617740475][@bibr15-1533034617740475][@bibr16-1533034617740475][@bibr17-1533034617740475][@bibr18-1533034617740475][@bibr19-1533034617740475][@bibr20-1533034617740475][@bibr21-1533034617740475]--[@bibr22-1533034617740475]^ However, none of the studies has been conducted in Hubei Chinese population. Moreover, the results from previous studies remain conflicting rather than conclusive. In view of this, a case--control study was performed to evaluate the association between the -149C\>T and -579G\>T polymorphisms and susceptibility to lung and gastric cancer in a Chinese population of Hubei province with larger sample size. Next, a meta-analysis combining the current study and previously published studies was further conducted to clarify the real impact of *DNMT3B* -149C\>T and -579G\>T polymorphisms on the risk of lung and gastric cancer in Chinese population.

Material and Methods {#section2-1533034617740475}
====================

Participants {#section3-1533034617740475}
------------

A total of 550 patients with lung cancer, 460 patients with gastric cancer, and 800 normal controls were recruited in the current study. All participants were biologically unrelated Chinese living in Hubei province. Nowadays, more and more Chinese are inclined to have a physical examination every year. The normal controls were selected from cancer-free individuals who visited Wuhan Xinzhou District People's Hospital for regular physical examinations between September 2014 and December 2016 or who volunteered to participate in the epidemiology survey during the same period. It was required that the normal controls passed all annual physical examinations in the latest 3 years. Patients with lung and gastric cancer were confirmed histopathologically and volunteers recruited from Hubei Cancer Hospital and Wuhan Xinzhou District People's Hospital between January 2015 and December 2016. This study was approved by the Ethical Committees of Wuhan University of Technology, and written informed consent for the genetics analysis was obtained from all participants or their guardians.

The Genotyping of DNMT3B Polymorphisms {#section4-1533034617740475}
--------------------------------------

Samples were collected into blood vacuum tubes containing EDTA and stored at 4°C. Genomic DNA was extracted within 1 week of sample collection by proteinase K digestion as described previously.^[@bibr23-1533034617740475]^ Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to detect the -149C\>T and -579G\>T polymorphisms of *DNMT3B* gene. The primers, length of PCR products, related restriction endonuclease as well as digested bands are shown in [Table 1](#table1-1533034617740475){ref-type="table"}. The PCR reaction was performed in a total of 15 μL containing 50 ng genomic DNA, 1.5 μL 10 × Taq Buffer (Mg^2+^ Plus), 0.2 μL 10 mmol/L deoxy-ribonucleoside triphosphate, 1-μL 1 mmol/L primers, and 0.5 U Taq polymerase (Takara Biotechnology Co Ltd, Dalian, China). The PCR products were then digested with 10-unit restriction enzymes following the manufacturer's instructions (Takara Biotechnology Co Ltd, Dalian, China). Digested fragments were separated by electrophoresis on 3% agarose gel and visualized under ultraviolet light with Gel-Red staining. For quality control, genotyping analysis was performed blind, with respect to case/control status, and repeated twice for all participants. The results of genotyping were 100% concordant. In order to confirm the genotyping results, 20% randomly selected PCR-amplified DNA samples were examined by DNA sequencing, and the results were also 100% concordant.

###### 

Primers and Restriction Enzymes of *DNMT3B* Polymorphisms for Genotyping.

![](10.1177_1533034617740475-table1)

  Locus                           Location                                  Primer Sequence (5'-3')          Annealing Temperature   Product   Enzyme, Digestion Temperature   Digested Bands
  ------------------------------- ----------------------------------------- -------------------------------- ----------------------- --------- ------------------------------- -----------------
  -149C\>T                        In the transcription start site           Forward: GCCACCCTACCACCTCTATTC   58^o^C                  153 bp    *BfaI*, 37^o^C                  C allele: 153bp
  Reverse: GGACACTCACTGGGGCTTAG   T allele: 131bp + 22bp                                                                                                                       
  -579G\>T                        In the exon 1B transcription start site   Forward: GCCAACCAAAGGTGGAACA     57^o^C                  169 bp    *PvuII*, 37^o^C                 G allele: 169bp
  Reverse: GAGGCACAGGCAGAAAGC     T allele: 104bp+65bp                                                                                                                         

Statistical Analysis {#section5-1533034617740475}
--------------------

The chi-square test was used to compare the difference in age, gender, smoking status, and alcohol status between patients and normal controls. Genotypic frequency of -149C\>T and -579G\>T polymorphisms were tested for departure from Hardy-Weinberg equilibrium (HWE) using the χ^2^ test. To evaluate the association between *DNMT3B* polymorphisms and cancer risk, odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by logistic regression analysis. Linkage disequilibrium (LD) plot was performed to test the -149C\>T and -579G\>T polymorphisms using *D'* as the measure of LD. SHEsis software (<http://analysis.bio-x.cn/myAnalysis.php>)^[@bibr24-1533034617740475]^ was used to test a possible association of statistically inferred haplotypes with cancer risk by a global test and haplotype-specific test, and haplotype frequencies were compared between the patients and the controls with Fisher exact test and logistic regression analysis. Statistical significance was established at *P* \<.05, and a Bonferroni correction for multiple testing was applied. The statistical analyses were performed using SPSS 15.0 software (SPSS, Chicago, Illinois).

Meta-Analysis {#section6-1533034617740475}
-------------

We searched the all publications updated to March 2017 from the PubMed, EMBASE, ISI Web of Science, China National Knowledge Infrastructure, and WanFang databases without language restriction. The following words were searched: "DNMT3B or DNA methyltransferase 3B", "rs2424913/-149C\>T", "rs1569686/-579G\>T", "lung cancer or gastric cancer" and "Chinese population". References listed in retrieved articles were also checked for missing information. Next, studies were eligible for inclusion in the meta-analysis if they met the following criteria: (1) studies on humans; (2) investigation of the *DNMT3B* -149C\>T polymorphism or *DNMT3B* -579G\>T polymorphism and the risk of lung cancer or gastric cancer; (3) case-control study design; (4) valid data were accessible to estimate the OR and its 95% CI; (5) HWE equilibrium should be established in control groups.

We calculated the departure from the HWE for the control group in each study using Pearson goodness-of-fit χ^2^ test. The analyses were conducted in Review Manager 5.3 (Cochrane Collaboration, Oxford, United Kingdom). The overall strength of an association between *DNMT3B* polymorphisms and cancer risk was assessed by crude ORs together with their corresponding 95% CIs. Heterogeneity was evaluated by the χ^2^ test of heterogeneity and the inconsistency index (*I* ^2^). By heterogeneity test, heterogeneity was considered significant when *P* value (*P* ~heterogeneity~) \< .1 was consistent with possible substantial heterogeneity. If *P* ~heterogeneity~ ≥ .1 we used the fixed-effect model to calculate the combined OR (the Mantel-Haenszel method),^[@bibr25-1533034617740475]^ otherwise, random-effects model (Der Simonian and Laird method) was conducted.^[@bibr26-1533034617740475]^ The significance of combined OR was determined by the *Z* test.

Results {#section7-1533034617740475}
=======

[Table 2](#table2-1533034617740475){ref-type="table"} showed us the frequency distributions of patients with lung cancer, patients with gastric cancer, and normal controls. There were no significant difference in the frequency distributions of age stratification, gender, smoking status, and drinking status between patients with lung cancer and normal controls as well as between patients with gastric cancer and normal controls, suggesting that matching based on these 4 variables were adequate.

###### 

Characteristics of Patients With Lung Cancer, Patients With Gastric Cancer, and Normal Controls.

![](10.1177_1533034617740475-table2)

  Variables        Patients With Lung Cancer   Patients With Gastric Cancer   Normal Controls   *P* Value^a^   *P* Value^b^   
  ---------------- --------------------------- ------------------------------ ----------------- -------------- -------------- ------
  Age, years       ≤60                         306 (55.6%)^c^                 252 (54.8%)       434 (54.3%)    .615           .855
  \>60             244 (44.4%)                 208 (45.2%)                    366 (45.7%)                                     
  Gender           Male                        373 (67.9%)                    323 (70.3%)       558 (69.7%)    .451           .862
  Female           177 (32.1%)                 137 (29.7%)                    242 (30.3%)                                     
  Smoking status   Ever                        150 (27.3%)                    132 (28.8%)       209 (26.1%)    .639           .323
  Never            400 (72.7%)                 328 (71.2%)                    591 (73.9%)                                     
  Alcohol status   Ever                        170 (31.0%)                    148 (32.1%)       237 (29.6%)    .613           .344
  Never            380 (69.0%)                 312 (67.9%)                    563 (70.4%)                                     

^a^Age, gender, smoking status, and alcohol status distributions of patients with lung cancer and normal controls were compared using 2-sided χ^2^ test.

^b^Age, gender, smoking status, and alcohol status distributions of patients with gastric cancer and normal controls were compared using 2-sided χ^2^ test.

^c^Values are represented as number (percentage).

The -149C\>T and -579G\>T polymorphisms were successfully genotyped in a total of 1810 participants. No significant deviations from HWE were observed for -149C\>T and -579G\>T in normal controls (*P* \> .05). The allele and genotype distributions of *DNMT3B* polymorphisms and their association with risk of lung and gastric cancer are presented in [Table 3](#table3-1533034617740475){ref-type="table"}. No association was found between -149C\>T and risk of lung or gastric cancer as well as between -579G\>T and lung cancer risk. However, it was showed that the frequency of -579 T allele was significantly higher among patients with gastric cancer than normal controls (*P* = .001, OR = 1.58, 95% CI = 1.22-2.04) after Bonferroni correction for multiple testing (0.05/12 = 0.004), indicating -579 T allele was associated with an increased risk of gastric cancer. Concordantly, we also found a significant association between -579TT genotype with increased risk of gastric cancer in 2 genetic models: TT vs TG (*P* = .001, OR = 1.62, 95%CI = 1.22-2.17) and TT vs TG+GG (*P* = .001, OR = 1.65, 95% CI = 1.25-2.19), and the association remained significant after Bonferroni correction for multiple testing (0.05/12 = 0.004). These results indicated that the *DNMT3B* -579G\>T polymorphism significantly increases the risk of gastric cancer.

###### 

Genotype and Allele Distributions of *DNMT3B* -149C\>T and -579G\>T Polymorphisms, and Their Association With the Risk of Lung and Gastric Cancer.

![](10.1177_1533034617740475-table3)

  *DNMT3B* Polymorphisms   I. Patients With Lung Cancer   II\. Patients With Gastric Cancer   III\. Normal Controls   HWE^a^   Logistic Regression, *P* ^b^, OR (95% CI)^c^                            
  ------------------------ ------------------------------ ----------------------------------- ----------------------- -------- ---------------------------------------------- ------------------------ ------------------------
  -149C\>T                                                                                                                                                                                             
   T                       1038 (94.4%)                   884 (96.1%)                         1522 (95.1%)                     T vs C                                         .381, 0.86 (0.61-1.21)   .264, 1.26 (0.84-1.88)
   C                       62 (5.6%)                      36 (3.9%)                           78 (4.9%)                                                                                                
   TT                      490 (89.1%)                    425 (92.3%)                         724 (90.4%)             0.940    TT vs TC                                       .427, 0.86 (0.60-1.24)   .257, 1.28 (0.84-1.95)
   TC                      58 (10.6%)                     34 (7.5%)                           74 (9.3%)                        TT vs CC                                       .697, 0.68 (0.10-4.82)   .896, 1.17 (0.11-13.0)
   CC                      2 (0.3%)                       1 (0.2%)                            2 (0.3%)                         TC vs CC                                       .810, 0.78 (0.11-5.73)   .946, 0.92 (0.08-10.5)
                                                                                                                               TT vs TC+CC                                    .398, 0.86 (0.60-1.23)   .255, 1.28 (0.84-1.94)
                                                                                                                               TT+TC vs CC                                    .707, 0.69 (0.10-4.90)   .909, 1.15 (0.10-12.7)
  -579G\>T                                                                                                                                                                                             
   T                       953 (86.7%)                    829 (90.1%)                         1364 (85.3%)                     T vs G                                         .311, 1.12 (0.90-1.40)   .001, 1.58 (1.22-2.04)
   G                       147 (13.4%)                    91 (9.9%)                           236 (14.7%)                                                                                              
   TT                      413 (75.1%)                    374 (81.4%)                         580 (72.5%)             0.693    TT vs TG                                       .302, 1.14 (0.89-1.48)   .001, 1.62 (1.22-2.17)
   TG                      127 (23.1%)                    81 (17.7%)                          204 (25.5%)                      TT vs GG                                       .749, 1.14 (0.51-2.54)   .161, 2.06 (0.75-5.68)
   GG                      10 (1.8%)                      5 (1.0%)                            16 (2.0%)                        TG vs GG                                       .993, 1.00 (0.44-2.26)   .651, 1.27 (0.45-3.58)
                                                                                                                               TT vs TG+GG                                    .289, 1.14 (0.89-1.47)   .001. 1.65 (1.25-2.19)
                                                                                                                               TT+TG vs GG                                    .811, 1.10 (0.50-2.45)   .230, 1.86 (0.68-5.10)

Abbreviations: CI, confidence interval; HWE, Hardy-Weinberg equilibrium; OR, odds ratio.

^a^Genotypic frequency of *DNMT3B* polymorphisms in normal controls were tested for departure from Hardy-Weinberg equilibrium (HWE) using the χ^2^ test.

^b^The *P* value was calculated using 2-sided χ^2^ test.

^c^OR (95% CI) was estimated by logistic regression analysis.

The LD analysis revealed a low LD between -149C\>T and -579G\>T in patients with gastric cancer (*D'* = 0.26), patients with lung cancer (*D'* = 0.35), and normal controls (*D'* = 0.41), which were consistent with the results from the Han Chinese data set of the International HapMap Consortium. Since the haplotype analysis could enhance the statistical power in the mapping of human complex trait loci,^[@bibr27-1533034617740475]^ the analysis of haplotypes consisting of -149C\>T/-579G\>T was performed to assess *DNMT3B* gene with lung and gastric cancer susceptibility in this study. As presented in [Table 4](#table4-1533034617740475){ref-type="table"}, none of the haplotypes was significantly associated with risk of lung cancer. However, when comparing patients having gastric cancer to normal controls, it showed a strong, significant difference in the overall distribution (global, *P* = .036). The frequency of haplotype -149T/-579 T was significantly higher in patients with gastric cancer than in normal controls (87.5% vs 83.4%, *P* = .006) at the significant level *P* \<.013 (0.05/4) using the Bonferroni correction, and logistic regression analysis indicated that haplotype -149T/-579 T increased the risk of gastric cancer (OR = 1.40, 95% CI = 1.10-1.77).

###### 

Association Between *DNMT3B* Haplotypes With Risk of Lung and Gastric Cancer.

![](10.1177_1533034617740475-table4)

  Haplotype^a^   I. Patients With Lung Cancer   II\. Patients With Gastric Cancer   III\. Normal Controls   I vs III   II vs III                                     
  -------------- ------------------------------ ----------------------------------- ----------------------- ---------- ----------- ------------------ ------- ------ ------------------
  -149C/-579G    0.024                          0.013                               0.024                   0.001      .985        1.00 (0.60-1.65)   3.434   .068   0.54 (0.28-1.05)
  -149C/-579T    0.033                          0.026                               0.032                   0.015      .902        1.03 (0.67-1.59)   0.675   .411   0.81 (0.50-1.33)
  -149T/-579G    0.091                          0.086                               0.110                   2.582      .108        0.81 (0.63-1.05)   3.722   .054   0.76 (0.58-1.00)
  -149T/-579T    0.852                          0.875                               0.834                   1.591      .207        1.15 (0.93-1.42)   7.697   .006   1.40 (1.10-1.77)
  Global test    1.000                          1.000                               1.000                   2.450      .484                           8.563   .036   

Abbreviations: CI, confidence interval; OR, odds ratio.

^a^The haplotype structure was -149C\>T/-579G\>T. All haplotypes with frequency \<0.01 in both case and control groups would be ignored in analysis.

^b^The *P* value was calculated using 2-sided χ^2^ test.

^c^OR (95% CI) was estimated by logistic regression analysis.

According to inclusion criteria, 9 previous studies were finally selected in the following meta-analysis.^[@bibr14-1533034617740475][@bibr15-1533034617740475][@bibr16-1533034617740475][@bibr17-1533034617740475][@bibr18-1533034617740475][@bibr19-1533034617740475][@bibr20-1533034617740475][@bibr21-1533034617740475]--[@bibr22-1533034617740475]^ [Table 5](#table5-1533034617740475){ref-type="table"} showed the main features of the current and previous studies that evaluated the association between -149C\>T or -579G\>T and lung or gastric cancer risk. In [Table 6](#table6-1533034617740475){ref-type="table"}, no association was observed between -149C\>T and risk of lung or gastric cancer as well as between -579G\>T and risk of lung cancer. In contrast, the -579G\>T was significantly associated with an increased risk of gastric cancer in 3 genetic models (T vs G, *P* \< 1×10^−5^, OR = 1.70, 95% CI = 1.36-2.13; TT vs TG, *P* \< 1×10^−5^, OR = 1.77, 95% CI = 1.38-2.28; TT vs TG+GG, *P* \< 1×10^−5^, OR = 1.80, 95% CI = 1.41-2.29) after Bonferroni correction for multiple testing (0.05/6 = 0.008). Interestingly, these results of the meta-analysis confirmed our current findings.

###### 

Characteristics of Current and Previous Studies in Chinese Population.

![](10.1177_1533034617740475-table5)

  References                                 Region         Cancer Type      Case (n)   Control (n)   Matching Y/N   Quality Control^a^ Y/N   HWE^b^                          
  ------------------------------------------ -------------- ---------------- ---------- ------------- -------------- ------------------------ ---------- ------------ --- --- -------
  -149C\>T                                                                   Total      T/C           TT/TC/CC       Total                    T/C        TT/TC/CC             
   Wang et al^[@bibr14-1533034617740475]^    Hebei          Gastric cancer   212        417/7         205/7/0        294                      573/15     279/15/0     Y   Y   0.654
   Zhang^[@bibr18-1533034617740475]^         Jiangsu        Gastric cancer   156        309/3         154/1/1        156                      311/1      155/1/0      Y   Y   0.968
   Hu et al^[@bibr15-1533034617740475]^      Jiangsu        Gastric cancer   259        516/2         257/2/0        262                      521/3      259/3/0      Y   Y   0.926
   Qiu et al^[@bibr22-1533034617740475]^     Jiangsu        Gastric cancer   233        462/4         229/4/0        208                      412/4      204/4/0      Y   Y   0.889
   Current study                             Hubei          Gastric cancer   460        884/36        425/34/1       800                      1522/78    724/74/2     Y   Y   0.940
   Yang^[@bibr17-1533034617740475]^          Jilin          Lung cancer      52         99/5          47/5/0         55                       107/3      52/3/0       Y   Y   0.835
   Zhang et al^[@bibr19-1533034617740475]^   Heilongjiang   Lung cancer      50         97/3          48/1/1         60                       118/2      58/2/0       Y   Y   0.896
   Current study                             Hubei          Lung cancer      550        1038/62       490/58/2       800                      1522/78    724/74/2     Y   Y   0.940
  -579G\>T                                                                   Total      T/G           TT/TG/GG       Total                    T/G        TT/TG/GG             
   Hu et al^[@bibr15-1533034617740475]^      Jiangsu        Gastric cancer   259        487/31        230/27/2       262                      461/63     203/55/4     Y   Y   0.901
   Zhang et al^[@bibr21-1533034617740475]^   Heilongjiang   Gastric cancer   50         93/7          43/7/0         60                       108/12     48/12/0      Y   Y   0.389
   Current study                             Hubei          Gastric cancer   460        829/91        374/81/5       800                      1364/236   580/204/16   Y   Y   0.693
   Liu et al^[@bibr16-1533034617740475]^     Heilongjiang   Lung cancer      174        327/21        154/19/1       135                      244/26     109/26/0     Y   Y   0.216
   Zhang et al^[@bibr20-1533034617740475]^   Heilongjiang   Lung cancer      98         175/21        77/21/0        105                      185/25     80/25/0      Y   Y   0.166
   Current study                             Hubei          Lung cancer      550        953/147       413/127/10     800                      1364/236   580/204/16   Y   Y   0.693

Abbreviation: HWE, Hardy-Weinberg equilibrium

^a^Quality control was conducted when sample of cases and controls was genotyped.

^b^Genotypic frequencies of -149C\>T and -579G\>T in normal controls were tested for departure from Hardy-Weinberg equilibrium (HWE) using the χ^2^ test.

###### 

Pooled ORs and 95% CIs in the Meta-Analysis.
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  Genetic Model                 Heterogeneity Test   Summary OR (95% CI)   Hypothesis Test   Studies (n)                            
  ----------------------------- -------------------- --------------------- ----------------- ------------------ ------ ------------ ---
  -149C\>T and gastric cancer                                                                                                       
   T vs C                       1.61                 .81                   0%                1.25 (0.89-1.76)   1.28   .20          5
   TT vs TC                     0.27                 .99                   0%                1.31 (0.92-1.88)   1.48   .14          5
   TT vs CC                     0.38                 .54                   0%                0.72 (0.12-4.35)   0.36   .72          2
   TC vs CC                     0.19                 .67                   0%                0.68 (0.09-5.04)   0.37   .71          2
   TT vs TC+CC                  0.85                 .93                   0%                1.29 (0.90-1.83)   1.39   .16          5
   TT+TC vs CC                  0.37                 .54                   0%                0.71 (0.12-4.30)   0.38   .71          2
  -149C\>T and lung cancer                                                                                                          
   T vs C                       0.53                 .77                   0%                0.83 (0.60-1.15)   1.15   .25          3
   TT vs TC                     0.65                 .72                   0%                0.85 (0.601.21)    0.90   .37          3
   TT vs CC                     0.22                 .64                   0%                0.52 (0.10-2.65)   0.79   .43          2
   TC vs CC                     0.39                 .53                   0%                0.57 (0.10-3.17)   0.64   .52          2
   TT vs TC+CC                  0.35                 .84                   0%                0.83 (0.59-1.17)   1.03   .30          3
   TT+TC vs CC                  0.23                 .63                   0%                0.52 (0.10-2.66)   0.79   .43          2
  -579G\>T and gastric cancer                                                                                                       
   T vs G                       1.45                 .48                   0%                1.69 (1.36-2.10)   4.73   \<1×10^−5^   3
   TT vs TG                     1.51                 .47                   0%                1.76 (1.38-2.24)   4.57   \<1×10^−5^   3
   TT vs GG                     0.01                 .93                   0%                2.11 (0.88-5.05)   1.68   .09          2
   TG vs GG                     0.06                 .80                   0%                1.19 (0.49-2.91)   0.39   .70          2
   TT vs TG+GG                  1.46                 .48                   0%                1.78 (1.41-2.25)   4.79   \<1×10^−5^   3
   TT+TG vs GG                  \<0.01               .94                   0%                1.89 (0.79-4.51)   1.43   .15          2
  -579G\>T and lung cancer                                                                                                          
   T vs G                       1.46                 .48                   0%                1.17 (0.96-1.43)   1.56   .12          3
   TT vs TG                     2.27                 .32                   12%               1.22 (0.98-1.52)   1.74   .08          3
   TT vs GG                     0.28                 .60                   0%                1.07 (0.50-2.32)   0.18   .86          2
   TG vs GG                     0.67                 .41                   0%                0.90 (0.41-1.97)   0.26   .79          2
   TT vs TG+GG                  1.90                 .39                   0%                1.21 (0.97-1.50)   1.71   .09          3
   TT+TG vs GG                  0.32                 .57                   0%                1.03 (0.48-2.22)   0.08   .93          2

Abbreviations: CI, confidence interval; OR, odds ratio.

Discussion {#section8-1533034617740475}
==========

Various studies have described the roles of -149C\>T and -579G\>T in different types of cancer including gastric cancer^[@bibr14-1533034617740475],[@bibr15-1533034617740475],[@bibr18-1533034617740475],[@bibr21-1533034617740475],[@bibr22-1533034617740475]^ and lung cancer.^[@bibr13-1533034617740475],[@bibr16-1533034617740475],[@bibr17-1533034617740475],[@bibr19-1533034617740475],[@bibr20-1533034617740475]^ Of the 10 studies that attempted to evaluate the association between -149C\>T or -579G\>T and susceptibility to lung cancer or gastric cancer, 9 studies focused on Chinese^[@bibr14-1533034617740475][@bibr15-1533034617740475][@bibr16-1533034617740475][@bibr17-1533034617740475][@bibr18-1533034617740475][@bibr19-1533034617740475][@bibr20-1533034617740475][@bibr21-1533034617740475]--[@bibr22-1533034617740475]^ and 1 on Korean.^[@bibr13-1533034617740475]^ However, none of the studies has been performed in Hubei Chinese population. Therefore, we analyzed the distribution of -149C\>T and -579G\>T and assessed their association with risk of gastric cancer and lung cancer in a Chinese population of Hubei province.

In this study, it was demonstrated that the -579 T allele was a harmful effect potentially exhibited by -579G\>T polymorphism in gastric tumorigenesis, which was consistent with the finding of Hu *et al* ^[@bibr15-1533034617740475]^ but not Zhang *et al* ^[@bibr21-1533034617740475]^ On the other hand, previous studies suggested a significant association between -579G\>T and lung cancer risk in Northeastern Chinese population^[@bibr16-1533034617740475]^ and Korean population,^[@bibr13-1533034617740475]^ but this association did not remain statistically in Zhang *et al* study^[@bibr20-1533034617740475]^ and the present study. One possibility for the discrepancy may be attributed to different environments, lifestyles, and genetic backgrounds among different ethnic populations. Admittedly, the Chinese populations from different geographic regions and small sample size may also contribute to the difference of the results. Of note, alongside previous findings,^[@bibr14-1533034617740475],[@bibr15-1533034617740475],[@bibr17-1533034617740475][@bibr18-1533034617740475]--[@bibr19-1533034617740475],[@bibr22-1533034617740475]^ our present results consistently suggested that -149C\>T was not associated with the risk of gastric or lung cancer in Chinese population.

To solve the discrepancies and the problem of inadequate statistical strength among previous studies,^[@bibr28-1533034617740475]^ a meta-analysis was further conducted to systematically evaluate the impacts of DNMT3B -149C\>T and -579G\>T polymorphisms on individuals' susceptibility to gastric and lung cancer in Chinese population. Interestingly, the pooled results further confirmed that -579G\>T was significantly associated with the risk of gastric cancer but not lung cancer, while -149C\>T was irrelevant to the risk of gastric and lung cancer. However, additional independent studies with larger sample sizes in Chinese populations across different geographical areas are still needed to validate or further reinforce our present findings.

The recent successful completion of the HapMap project suggested that haplotype analysis would enhance the statistical power in the mapping of human complex trait loci, with the potential of reducing the sample size of association studies.^[@bibr27-1533034617740475],[@bibr29-1533034617740475],[@bibr30-1533034617740475]^ Our study also included a haplotype study to assess the potential combined effect of -149C\>T and -579G\>T on risk of lung and gastric cancer. The LD analysis of -149C\>T and -579G\>T indicated a low LD with each other, suggesting that -149C\>T and -579G\>T might be sufficient to capture some of the haplotype structures in *DNMT3B* gene.^[@bibr31-1533034617740475]^ The haplotype -149T/-579 T was significantly associated with an increased risk of gastric cancer, which suggested that -149C\>T and -579G\>T might act together to affect gastric tumorigenesis. Since -579 T allele was associated with an increased risk of gastric cancer, it was speculated that the -579G\>T might be used as a risk biomarker for gastric cancer prediction in Chinese population. To our knowledge, this is the first report of a significant association between haplotype -149T/-579 T of *DNMT3B* gene and gastric cancer, which needs to be further confirmed.

Collectively, our results demonstrated that the *DNMT3B* -579G\>T polymorphism is significantly associated with an increased risk of gastric cancer but not lung cancer in Chinese population. In addition, the haplotype -149T/-579 T, carrying the risk -579 T allele, significantly increases the susceptibility of individuals to gastric cancer in Chinese population. Besides, the *DNMT3B* -149C\>T polymorphism does not contribute to the risk of lung or gastric cancer in Chinese population. These reported findings may initiate novel prediction and prevention strategy for lung and gastric cancer in Chinese population. However, further confirmatory studies should be undertaken in other ethnic populations because the present observations involved only Chinese population.
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CI

:   confidence interval

HWE

:   Hardy-Weinberg equilibrium

LD

:   Linkage disequilibrium

OR

:   odds ratio

PCR-RFLP

:   polymerase chain reaction-restriction fragment length polymorphism

SNP

:   single nucleotide polymorphism.
